Impact Biomedical Inc. (IBO): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$1.15M
Year ended 2025-12-31
$1.14M
Trailing 12 months to 2026-06-30
+0.9%
3-year compound annual growth
2022-12-31: $1.11M2023-12-31: $1.12M2024-12-31: $1.12M2025-12-31: $1.15M$1.15M
2022-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$1.15M+2.3%2026-03-11, From 2025-01-01
2024-12-31$1.12M-0.1%2026-03-11, From 2024-01-01
2023-12-31$1.12M+0.6%2025-03-28, From 2023-01-01
2022-12-31$1.11Mn/a2024-02-20, From 2022-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Impact Biomedical Inc. (IBO)2025-12-31$1.15M+2.3%
Lyell Immunopharma, Inc. (LYEL)2025-12-31$11.54M-41.2%
Talphera, Inc. (TLPH)2024-12-31$0-100.0%
Skinvisible, Inc. (SKVI)2025-12-31$20.2K-1.0%
HCW Biologics Inc. (HCWB)2025-12-31$1.04M-12.0%
Avalo Therapeutics, Inc. (AVTX)2025-12-31$344.0K+103.6%
Connect Biopharma Holdings Ltd (CNTB)2025-12-31$704.0K+6.7%
Incannex Healthcare Inc. (IXHL)2025-06-30$246.0K+138.8%
Actinium Pharmaceuticals, Inc. (ATNM)2025-12-31$173.0K-12.2%

Compare IBO, LYEL, TLPH, SKVI side by side · Screen every company in Pharmaceutical Preparations ↗